clinical trial · NCT05906576
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Taizhou Mabtech Pharmaceutical Co.,Ltd·phase4·recruiting·n = 30
Crohn DiseaseInfliximab
brief summary
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
started
Sep 21, 2023
primary completion
Nov 1, 2026
completion
Feb 1, 2027
last updated
Sep 30, 2026
detailed description
This is a prospective, multicenter registry study in Chinese pediatric Crohn's disease patients. A total of 30 subjects were planned to be enrolled and treated with Infliximab. Subjects were observed for 102 weeks after administration to evaluate the clinical efficacy and safety of infliximab in the treatment of children with Crohn's disease in a real diagnostic setting.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol